Literature DB >> 2674457

Clinical use of recombinant human hematopoietic growth factors.

J Laver1, M A Moore.   

Abstract

Hematopoietic growth factors comprise a family of hematopoietic regulators with biologic specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. The biologic specificities of these factors are highly complex, dose dependent, and frequently overlapping. Recent advances in the cloning of hematopoietic growth factor genes and the availability of recombinant material have led investigators to conduct clinical trials with these agents. Some of these factors have been studied and used in chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes. In this paper, we review the experience with growth factors that have been tested and that currently are being introduced in clinical trials. In addition, we report some factors with possible future interest for clinicians and researchers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674457     DOI: 10.1093/jnci/81.18.1370

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  10 in total

Review 1.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

Review 2.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

Review 3.  Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.

Authors:  G Schwab; T Hecht
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

4.  Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia.

Authors:  L Panasci; G Shenouda; L Begin; M Pollak; A Reinke; R Margolese
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

6.  Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.

Authors:  G Visani; D Damiani; A Cenacchi; D Russo; G Revignas; B Gamberi; R Fanin; M Fogli; M Baccarani; S Tura
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

7.  Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice.

Authors:  F Abe; A Matsuda; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 8.  The aged patient with lung cancer. Management recommendations.

Authors:  V Zagonel; U Tirelli; D Serraino; G Lo Re; M C Merola; M Mascarin; M G Trovò; A Carbone; S Monfardini
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

9.  Interstitial pneumonia in patients receiving granulocyte colony-stimulating factor during chemotherapy: survey in Japan 1991-96.

Authors:  N Niitsu; S Iki; K Muroi; S Motomura; M Murakami; H Takeyama; A Ohsaka; A Urabe
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer.

Authors:  K Eguchi; T Shinkai; Y Sasaki; T Tamura; Y Ohe; K Nakagawa; M Fukuda; K Yamada; A Kojima; F Oshita
Journal:  Jpn J Cancer Res       Date:  1990-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.